Revvity (RVTY) reported Q1 adjusted earnings Monday of $1.01 per diluted share, up from $0.98 a year earlier.
Analysts polled by FactSet expected $0.95.
Revenue for the quarter ended March 31 was $664.8 million, up from $649.9 million a year earlier.
Analysts surveyed by FactSet expected $661.0 million.
For 2025, the biopharmaceutical company maintained its adjusted EPS guidance of $4.90 to $5.00 while raising its revenue forecast to $2.83 billion to $2.87 billion, up from its previous projection of $2.80 billion to $2.85 billion.
Analysts polled by FactSet expect non-GAAP EPS of $4.92 on revenue of $2.83 billion.
Shares of the company were up nearly 5% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。